Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
MWN-AI** Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced its participation in several key events scheduled for March 2026. The company will engage in a fireside chat presentation at the TD Cowen 46th Annual Health Care Conference, taking place from March 2-4, 2026, with the presentation slated for March 2 at 11:50 a.m. EST. Following this, it will also be present at the Leerink 2026 Global Healthcare Conference, with a fireside chat scheduled for March 9 at 2:20 p.m. EST.
Additionally, Arrowhead will partake in the 2026 Jefferies Biotech on the Beach Summit from March 9-11, 2026, participating in an investor group dinner on March 9 and holding investor 1x1 meetings on March 11. Lastly, the company is scheduled for investor 1x1 meetings at the Barclays 28th Annual Global Healthcare Conference, occurring from March 10-12, with meetings on March 10.
Arrowhead Pharmaceuticals is at the forefront of developing innovative medicines that address intractable diseases through a unique approach of gene silencing using RNA interference (RNAi). This technique effectively inhibits the expression of specific genes to combat disease-causing proteins, using a versatile portfolio of RNA chemistries and efficient delivery methods.
Investors and stakeholders can access presentation materials and webcasts through the Events and Presentations section on Arrowhead's website.
Those interested in the latest updates can follow Arrowhead on various social media platforms or join their email list for direct communications. As a forward-looking company, Arrowhead emphasizes potential developments and opportunities in its future endeavors, while also acknowledging the risks inherent in the biotech industry.
MWN-AI** Analysis
As Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) approaches a series of key investor events in March 2026, investors should maintain a keen focus on the company’s unique RNA interference (RNAi) therapeutic platform and its implications for future growth.
Participation in high-profile conferences, such as the TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Jefferies Biotech on the Beach Summit, provides key opportunities to highlight the company's advancements and pipeline potential. These events offer not only a platform for management to share insights on clinical progress but also to engage directly with investors through 1x1 meetings. Attendees will likely seek clarity on Arrowhead's ongoing clinical trials and anticipated milestones, which are pivotal for assessing its trajectory within the competitive biotech landscape.
Arrowhead focuses on developing innovative therapies targeting intractable diseases by silencing genes responsible for these conditions—an area ripe for investment given the growing emphasis on biotechnology solutions. Continued investment in research and development, coupled with strategic collaborations, could enhance the company's value proposition. The expectation of forthcoming data releases and potential partnerships from these presentations could be key catalysts for stock performance.
While the company faces inherent risks typical of biotech ventures—such as regulatory hurdles and the success of clinical trials—investors should weigh these risks against the vast potential of RNAi therapeutics in treating previously unmanageable conditions. Following Arrowhead’s performance over the next few months leading up to these conferences can provide valuable insights into potential trading strategies.
In conclusion, Arrowhead's strategic positioning and upcoming events offer a compelling narrative for investors. Positioning oneself to react to news and data emerging from these conferences could yield favorable returns in an often volatile market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
TD Cowen 46th Annual Health Care Conference – March 2-4, 2026
Type: Fireside Chat Presentation
Date/Time: March 2, 2026, 11:50 a.m. EST
Leerink 2026 Global Healthcare Conference – March 8-11, 2026
Type: Fireside Chat Presentation
Date/Time: March 9, 2026, 2:20 p.m. EST
2026 Jefferies Biotech on the Beach Summit – March 9-11, 2026
Type: Investor Group Dinner
Date/Time: March 9, 2026
Type: Investor 1x1 Meetings
Date/Time: March 11, 2026
Barclays 28th Annual Global Healthcare Conference – March 10-12, 2026
Type: Investor 1x1 Meetings
Date/Time: March 10, 2026
Presentation materials and webcast links, if applicable, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com , or follow us on X (formerly Twitter) at @ArrowheadPharma , LinkedIn , Facebook , and Instagram . To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260224346194/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com
FAQ**
What are the key goals Arrowhead Pharmaceuticals Inc. (ARWR) aims to achieve during its upcoming presentations at the TD Cowen and Leerink healthcare conferences in March 2026?
How does Arrowhead Pharmaceuticals Inc. (ARWR) plan to leverage RNA interference technology in its drug development strategy moving forward?
What updates can investors expect from Arrowhead Pharmaceuticals Inc. (ARWR) regarding its clinical trial progress during the investor meetings at the Jefferies and Barclays conferences?
How does Arrowhead Pharmaceuticals Inc. (ARWR) assess the potential risks and uncertainties associated with its product pipeline as outlined in the recent forward-looking statements?
**MWN-AI FAQ is based on asking OpenAI questions about Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR).
NASDAQ: ARWR
ARWR Trading
0.68% G/L:
$59.59 Last:
1,083,621 Volume:
$60.06 Open:
